Across TCGA pan-cancer cohorts, ZGPAT mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ZGPAT data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ZGPAT mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ZGPAT expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

HNSC, CCRCC, and LSCC are the cancer types where ZGPAT mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	III,IV	0.793	0.505	.003	58	view →
CCRCC	DFS	Median	II,III,IV	0.771	0.953	.013	2	view →
LSCC	DFS	Quartile	III,IV	0.422	0.859	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: ZGPAT tumor-vs-normal RNA expression · all ZGPAT data types